562 related articles for article (PubMed ID: 25915588)
21. Current recommendations for the Japanese encephalitis vaccine.
Chen HL; Chang JK; Tang RB
J Chin Med Assoc; 2015 May; 78(5):271-5. PubMed ID: 25841620
[TBL] [Abstract][Full Text] [Related]
22. Safety of Japanese encephalitis vaccines.
Hu YL; Lee PI
Hum Vaccin Immunother; 2021 Nov; 17(11):4259-4264. PubMed ID: 34613870
[TBL] [Abstract][Full Text] [Related]
23. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
24. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.
Lobigs M; Pavy M; Hall RA; Lobigs P; Cooper P; Komiya T; Toriniwa H; Petrovsky N
J Gen Virol; 2010 Jun; 91(Pt 6):1407-17. PubMed ID: 20130134
[TBL] [Abstract][Full Text] [Related]
25. Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysis.
Furuya-Kanamori L; Xu C; Doi SAR; Clark J; Wangdi K; Mills DJ; Lau CL
Vaccine; 2021 Jul; 39(32):4429-4436. PubMed ID: 34175128
[TBL] [Abstract][Full Text] [Related]
26. Use of the live attenuated Japanese Encephalitis vaccine SA 14-14-2 in children: A review of safety and tolerability studies.
Ginsburg AS; Meghani A; Halstead SB; Yaich M
Hum Vaccin Immunother; 2017 Oct; 13(10):2222-2231. PubMed ID: 28841362
[TBL] [Abstract][Full Text] [Related]
27. Characterization of immune responses induced by inactivated, live attenuated and DNA vaccines against Japanese encephalitis virus in mice.
Li J; Chen H; Wu N; Fan D; Liang G; Gao N; An J
Vaccine; 2013 Aug; 31(38):4136-42. PubMed ID: 23845821
[TBL] [Abstract][Full Text] [Related]
28. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.
Rabe IB; Miller ER; Fischer M; Hills SL
Vaccine; 2015 Jan; 33(5):708-12. PubMed ID: 25498208
[TBL] [Abstract][Full Text] [Related]
29. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
Appaiahgari MB; Vrati S
Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
[TBL] [Abstract][Full Text] [Related]
31. Persistence of IgM Antibodies after Vaccination with Live Attenuated Japanese Encephalitis Vaccine.
Hills SL; Van Keulen A; Feser J; Panella A; Letson GW; Staples JE; Marfin AA; Brault AC
Am J Trop Med Hyg; 2020 Nov; 104(2):576-579. PubMed ID: 33236716
[TBL] [Abstract][Full Text] [Related]
32. Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China.
Liu X; Yu Y; Li M; Liang G; Wang H; Jia L; Dong G
Vaccine; 2011 Mar; 29(11):2127-30. PubMed ID: 21237278
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of Vero Cell Culture-derived Japanese Encephalitis Vaccine in Pediatric and Young Hematopoietic Stem Cell Transplantation Recipients.
Assawawiroonhakarn S; Apiwattanakul N; Pakakasama S; Hongeng S; Anurathapan U; Yoksan S; Klinmalai C; Sae-Chew P; Techasaensiri C
Pediatr Infect Dis J; 2021 Mar; 40(3):264-268. PubMed ID: 33427799
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.
Tauber E; Kollaritsch H; Korinek M; Rendi-Wagner P; Jilma B; Firbas C; Schranz S; Jong E; Klingler A; Dewasthaly S; Klade CS
Lancet; 2007 Dec; 370(9602):1847-53. PubMed ID: 18061060
[TBL] [Abstract][Full Text] [Related]
35. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.
Feroldi E; Pancharoen C; Kosalaraksa P; Watanaveeradej V; Phirangkul K; Capeding MR; Boaz M; Gailhardou S; Bouckenooghe A
Hum Vaccin Immunother; 2012 Jul; 8(7):929-37. PubMed ID: 22777096
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
[TBL] [Abstract][Full Text] [Related]
37. Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine.
Kuzuhara S; Nakamura H; Hayashida K; Obata J; Abe M; Sonoda K; Nishiyama K; Sugawara K; Takeda K; Honda T; Matsui H; Shigaki T; Kino Y; Mizokami H; Tanaka M; Mizuno K; Ueda K
Vaccine; 2003 Nov; 21(31):4519-26. PubMed ID: 14575762
[TBL] [Abstract][Full Text] [Related]
38. T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine.
Wang R; Zhen Z; Turtle L; Hou B; Li Y; Wu N; Gao N; Fan D; Chen H; An J
Appl Microbiol Biotechnol; 2020 Aug; 104(15):6779-6789. PubMed ID: 32556415
[TBL] [Abstract][Full Text] [Related]
39. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.
Lyons A; Kanesa-thasan N; Kuschner RA; Eckels KH; Putnak R; Sun W; Burge R; Towle AC; Wilson P; Tauber E; Vaughn DW
Vaccine; 2007 Apr; 25(17):3445-53. PubMed ID: 17241714
[TBL] [Abstract][Full Text] [Related]
40. Partial cross-protection between Japanese encephalitis virus genotype I and III in mice.
Wei J; Wang X; Zhang J; Guo S; Pang L; Shi K; Liu K; Shao D; Qiu Y; Liu L; Widén F; Li B; Ma Z
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007601. PubMed ID: 31374086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
